HUP0201297A3 - Ziprasidone suspension - Google Patents

Ziprasidone suspension

Info

Publication number
HUP0201297A3
HUP0201297A3 HU0201297A HUP0201297A HUP0201297A3 HU P0201297 A3 HUP0201297 A3 HU P0201297A3 HU 0201297 A HU0201297 A HU 0201297A HU P0201297 A HUP0201297 A HU P0201297A HU P0201297 A3 HUP0201297 A3 HU P0201297A3
Authority
HU
Hungary
Prior art keywords
ziprasidone
suspension
ziprasidone suspension
Prior art date
Application number
HU0201297A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0201297(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HUP0201297A2 publication Critical patent/HUP0201297A2/hu
Publication of HUP0201297A3 publication Critical patent/HUP0201297A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Dental Preparations (AREA)
HU0201297A 1999-05-27 2000-05-08 Ziprasidone suspension HUP0201297A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27

Publications (2)

Publication Number Publication Date
HUP0201297A2 HUP0201297A2 (en) 2002-08-28
HUP0201297A3 true HUP0201297A3 (en) 2005-09-28

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201297A HUP0201297A3 (en) 1999-05-27 2000-05-08 Ziprasidone suspension

Country Status (50)

Country Link
EP (1) EP1181018B1 (hu)
JP (1) JP3942827B2 (hu)
KR (1) KR100477782B1 (hu)
CN (1) CN1196486C (hu)
AP (1) AP1409A (hu)
AR (1) AR022643A1 (hu)
AT (1) ATE234097T1 (hu)
AU (1) AU777413B2 (hu)
BG (1) BG65367B1 (hu)
BR (1) BR0010990A (hu)
CA (1) CA2371550C (hu)
CO (1) CO5170458A1 (hu)
CR (1) CR6506A (hu)
CU (1) CU23223B7 (hu)
CZ (1) CZ20014230A3 (hu)
DE (1) DE60001649T2 (hu)
DK (1) DK1181018T3 (hu)
DZ (1) DZ3049A1 (hu)
EA (1) EA003907B1 (hu)
EE (1) EE04704B1 (hu)
ES (1) ES2191618T3 (hu)
GC (1) GC0000190A (hu)
GE (1) GEP20033113B (hu)
GT (1) GT200000081A (hu)
HK (1) HK1046366B (hu)
HN (1) HN2000000071A (hu)
HR (1) HRP20010878B1 (hu)
HU (1) HUP0201297A3 (hu)
IL (2) IL145950A0 (hu)
IS (1) IS2396B (hu)
MA (1) MA26741A1 (hu)
MX (1) MXPA01012124A (hu)
MY (1) MY127891A (hu)
NO (1) NO320296B1 (hu)
NZ (1) NZ514764A (hu)
OA (1) OA11946A (hu)
PA (1) PA8495801A1 (hu)
PE (1) PE20010127A1 (hu)
PL (1) PL196867B1 (hu)
RS (1) RS50089B (hu)
SI (1) SI1181018T1 (hu)
SK (1) SK284590B6 (hu)
SV (1) SV2001000085A (hu)
TN (1) TNSN00112A1 (hu)
TR (1) TR200103392T2 (hu)
TW (1) TWI263498B (hu)
UA (1) UA59491C2 (hu)
UY (1) UY26166A1 (hu)
WO (1) WO2000072847A1 (hu)
ZA (1) ZA200109692B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20080015955A (ko) 1999-10-29 2008-02-20 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
NZ534746A (en) * 2002-03-12 2006-06-30 Bristol Myers Squibb Co Palatable oral suspension and method
EP1575616A2 (en) * 2002-10-25 2005-09-21 Pfizer Products Inc. Novel injectable depot formulations
PL375603A1 (en) * 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
EP1418492B1 (en) 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
AU2006285349A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
HRP20010878B1 (en) 2007-03-31
CO5170458A1 (es) 2002-06-27
YU76701A (sh) 2005-07-19
DZ3049A1 (fr) 2004-03-27
EA200101131A1 (ru) 2002-04-25
RS50089B (sr) 2009-01-22
AR022643A1 (es) 2002-09-04
EE04704B1 (et) 2006-10-16
NO20015755L (no) 2002-01-23
NO20015755D0 (no) 2001-11-26
HRP20010878A2 (en) 2003-06-30
NZ514764A (en) 2004-04-30
DK1181018T3 (da) 2003-04-22
CU23223B7 (es) 2007-08-30
CA2371550C (en) 2007-01-02
HN2000000071A (es) 2001-02-02
MY127891A (en) 2006-12-29
UA59491C2 (uk) 2003-09-15
BG106153A (bg) 2002-06-28
PL352826A1 (en) 2003-09-08
CR6506A (es) 2004-03-24
ATE234097T1 (de) 2003-03-15
CA2371550A1 (en) 2000-12-07
BG65367B1 (bg) 2008-04-30
EP1181018B1 (en) 2003-03-12
ES2191618T3 (es) 2003-09-16
KR20020048307A (ko) 2002-06-22
BR0010990A (pt) 2002-03-05
CN1196486C (zh) 2005-04-13
IL145950A (en) 2007-12-03
SK284590B6 (sk) 2005-07-01
SK16782001A3 (sk) 2002-09-10
EA003907B1 (ru) 2003-10-30
MXPA01012124A (es) 2002-06-04
PE20010127A1 (es) 2001-02-06
UY26166A1 (es) 2000-12-29
OA11946A (en) 2006-04-13
EE200100633A (et) 2003-02-17
GT200000081A (es) 2001-11-16
IL145950A0 (en) 2002-07-25
HK1046366B (zh) 2005-07-29
JP3942827B2 (ja) 2007-07-11
PA8495801A1 (es) 2001-12-14
GEP20033113B (en) 2003-11-25
AU777413B2 (en) 2004-10-14
GC0000190A (en) 2006-03-29
DE60001649T2 (de) 2003-08-21
AP2001002346A0 (en) 2001-12-31
IS2396B (is) 2008-08-15
ZA200109692B (en) 2002-11-26
TWI263498B (en) 2006-10-11
EP1181018A1 (en) 2002-02-27
MA26741A1 (fr) 2004-12-20
NO320296B1 (no) 2005-11-21
WO2000072847A1 (en) 2000-12-07
PL196867B1 (pl) 2008-02-29
TNSN00112A1 (fr) 2005-11-10
CZ20014230A3 (cs) 2002-08-14
HK1046366A1 (en) 2003-01-10
TR200103392T2 (tr) 2002-11-21
SI1181018T1 (en) 2003-06-30
AP1409A (en) 2005-06-13
DE60001649D1 (de) 2003-04-17
AU4138500A (en) 2000-12-18
IS6134A (is) 2001-10-30
KR100477782B1 (ko) 2005-03-21
JP2003500449A (ja) 2003-01-07
CN1352560A (zh) 2002-06-05
SV2001000085A (es) 2001-11-08
HUP0201297A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
IL137707A0 (en) Suspension device
GC0000190A (en) Ziprasidone suspension
GB9903584D0 (en) Modified calycins
EG22674A (en) Ectroparasiticidal aquequs suspension formulations
EP1156940A4 (en) BALANCED SUSPENSION SYSTEM
GB9916431D0 (en) Suspension strut
IL149498A0 (en) Suspension comprising oxcarbazepine
GB9906447D0 (en) Suspension arrangements
GB2348405B (en) Vehicle suspension
DE60044882D1 (en) Ie
GB2371332B (en) Independent suspension
TW595555U (en) Suspension
GB0116051D0 (en) Vehicle suspension
GB9905498D0 (en) Expression
GB9920764D0 (en) Suspension device
GB9929736D0 (en) Suspension point
TW450036U (en) Suspension card set
EG24008A (en) Ziprasidone formulations
GB9913541D0 (en) Suspension file
GB9900040D0 (en) Suspension system
PL333726A1 (en) Suspension system
SI1239832T1 (en) Suspension comprising oxcarbazepine
GB9926101D0 (en) Headstock II
GB9927510D0 (en) Teleportation
GB9927987D0 (en) Neo-baby clear

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees